DK3880818T3 - Nukleinsyrer til inhibering af ekspression af LPA i en celle - Google Patents
Nukleinsyrer til inhibering af ekspression af LPA i en celle Download PDFInfo
- Publication number
- DK3880818T3 DK3880818T3 DK19801033.2T DK19801033T DK3880818T3 DK 3880818 T3 DK3880818 T3 DK 3880818T3 DK 19801033 T DK19801033 T DK 19801033T DK 3880818 T3 DK3880818 T3 DK 3880818T3
- Authority
- DK
- Denmark
- Prior art keywords
- lpa
- cell
- nucleic acids
- inhibiting expression
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2018/081106 WO2019092283A1 (en) | 2017-11-13 | 2018-11-13 | Nucleic acids for inhibiting expression of lpa in a cell |
| EP19174466 | 2019-05-14 | ||
| PCT/EP2019/081158 WO2020099476A1 (en) | 2018-11-13 | 2019-11-13 | Nucleic acids for inhibiting expression of lpa in a cell |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3880818T3 true DK3880818T3 (da) | 2022-12-05 |
Family
ID=66554180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19801033.2T DK3880818T3 (da) | 2018-11-13 | 2019-11-13 | Nukleinsyrer til inhibering af ekspression af LPA i en celle |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20220002722A1 (enExample) |
| EP (2) | EP3880818B1 (enExample) |
| JP (1) | JP7245328B2 (enExample) |
| KR (1) | KR102553386B1 (enExample) |
| CN (2) | CN113227372A (enExample) |
| AU (1) | AU2019380628B2 (enExample) |
| CA (1) | CA3119239C (enExample) |
| CL (1) | CL2021001225A1 (enExample) |
| CO (1) | CO2021007372A2 (enExample) |
| CR (1) | CR20210301A (enExample) |
| DK (1) | DK3880818T3 (enExample) |
| EA (1) | EA202190895A1 (enExample) |
| ES (1) | ES2932295T3 (enExample) |
| FI (1) | FI3880818T3 (enExample) |
| HR (1) | HRP20221358T1 (enExample) |
| HU (1) | HUE060703T2 (enExample) |
| IL (1) | IL283159B2 (enExample) |
| LT (1) | LT3880818T (enExample) |
| MA (1) | MA58208B1 (enExample) |
| MX (1) | MX2021005590A (enExample) |
| PE (1) | PE20211282A1 (enExample) |
| PH (1) | PH12021550801B1 (enExample) |
| PL (1) | PL3880818T3 (enExample) |
| PT (1) | PT3880818T (enExample) |
| RS (1) | RS63778B1 (enExample) |
| SA (1) | SA521421963B1 (enExample) |
| SG (1) | SG11202103882QA (enExample) |
| SI (1) | SI3880818T1 (enExample) |
| SM (1) | SMT202300050T1 (enExample) |
| WO (1) | WO2020099476A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11015198B2 (en) * | 2017-04-05 | 2021-05-25 | Silence Therapeutics Gmbh | Products and compositions |
| CN119120476A (zh) | 2017-11-13 | 2024-12-13 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中lpa的表达的核酸 |
| AU2019380628B2 (en) | 2018-11-13 | 2024-10-31 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of LPA in a cell |
| EP4229201A1 (en) | 2020-10-16 | 2023-08-23 | Sanofi | Rna compositions and methods for inhibiting lipoprotein(a) |
| US20250283076A1 (en) * | 2021-09-14 | 2025-09-11 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| KR20240103025A9 (ko) | 2021-11-16 | 2025-12-10 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법 |
| TW202345865A (zh) * | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| WO2023152194A1 (en) | 2022-02-09 | 2023-08-17 | Silence Therapeutics Gmbh | Therapeutic inhibition of lpa expression |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| CN115044584A (zh) * | 2022-06-10 | 2022-09-13 | 上海鼎新基因科技有限公司 | 一种siRNA体外稳定性检测方法 |
| WO2024013334A1 (en) * | 2022-07-15 | 2024-01-18 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of agt in a cell |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| KR20250131826A (ko) * | 2023-01-13 | 2025-09-03 | 일라이 릴리 앤드 캄파니 | 치료 올리고뉴클레오티드-함유 제약 조성물 및 그를 사용한 투여 요법 |
| WO2024227458A2 (zh) * | 2023-08-22 | 2024-11-07 | 成都先衍生物技术有限公司 | 一种靶向AGT基因表达的siRNA及其缀合物和用途 |
| UY40897A (es) | 2023-09-21 | 2025-03-31 | Ionis Pharmaceuticals Inc | Compuestos y métodos para inhibir lpa |
| TW202540420A (zh) | 2023-11-15 | 2025-10-16 | 大陸商北京加科瑞康醫藥科技有限公司 | 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途 |
| WO2026046152A1 (zh) * | 2024-08-26 | 2026-03-05 | 倍臻生物技术（苏州）有限公司 | 修饰的双链核糖核酸及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US7259150B2 (en) * | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| US20060160759A1 (en) | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
| CN101278059A (zh) * | 2005-07-28 | 2008-10-01 | 肿瘤疗法科学股份有限公司 | 诊断和治疗肾细胞癌的方法 |
| US20110110886A1 (en) | 2008-06-13 | 2011-05-12 | Yale University | Small molecule inhibitors of autotaxin and methods of use |
| US9364495B2 (en) * | 2009-10-20 | 2016-06-14 | Roche Innovation Center Copenhagen A/S | Oral delivery of therapeutically effective LNA oligonucleotides |
| WO2014205451A2 (en) * | 2013-06-21 | 2014-12-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| US20160272970A1 (en) * | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| EP3228326A1 (en) | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| US11015198B2 (en) | 2017-04-05 | 2021-05-25 | Silence Therapeutics Gmbh | Products and compositions |
| CN119120476A (zh) * | 2017-11-13 | 2024-12-13 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中lpa的表达的核酸 |
| WO2019092282A1 (en) * | 2017-11-13 | 2019-05-16 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of aldh2 in a cell |
| AU2019380628B2 (en) | 2018-11-13 | 2024-10-31 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of LPA in a cell |
-
2019
- 2019-11-13 AU AU2019380628A patent/AU2019380628B2/en active Active
- 2019-11-13 MX MX2021005590A patent/MX2021005590A/es unknown
- 2019-11-13 PT PT198010332T patent/PT3880818T/pt unknown
- 2019-11-13 IL IL283159A patent/IL283159B2/en unknown
- 2019-11-13 KR KR1020217017471A patent/KR102553386B1/ko active Active
- 2019-11-13 HR HRP20221358TT patent/HRP20221358T1/hr unknown
- 2019-11-13 EP EP19801033.2A patent/EP3880818B1/en active Active
- 2019-11-13 PL PL19801033.2T patent/PL3880818T3/pl unknown
- 2019-11-13 PE PE2021000650A patent/PE20211282A1/es unknown
- 2019-11-13 DK DK19801033.2T patent/DK3880818T3/da active
- 2019-11-13 JP JP2021525771A patent/JP7245328B2/ja active Active
- 2019-11-13 ES ES19801033T patent/ES2932295T3/es active Active
- 2019-11-13 FI FIEP19801033.2T patent/FI3880818T3/fi active
- 2019-11-13 EA EA202190895A patent/EA202190895A1/ru unknown
- 2019-11-13 HU HUE19801033A patent/HUE060703T2/hu unknown
- 2019-11-13 CN CN201980074785.8A patent/CN113227372A/zh active Pending
- 2019-11-13 PH PH1/2021/550801A patent/PH12021550801B1/en unknown
- 2019-11-13 CR CR20210301A patent/CR20210301A/es unknown
- 2019-11-13 WO PCT/EP2019/081158 patent/WO2020099476A1/en not_active Ceased
- 2019-11-13 SM SM20230050T patent/SMT202300050T1/it unknown
- 2019-11-13 LT LTEPPCT/EP2019/081158T patent/LT3880818T/lt unknown
- 2019-11-13 CN CN202510076171.0A patent/CN119842706A/zh active Pending
- 2019-11-13 EP EP22197500.6A patent/EP4219712A3/en not_active Withdrawn
- 2019-11-13 RS RS20221119A patent/RS63778B1/sr unknown
- 2019-11-13 MA MA58208A patent/MA58208B1/fr unknown
- 2019-11-13 SI SI201930387T patent/SI3880818T1/sl unknown
- 2019-11-13 SG SG11202103882QA patent/SG11202103882QA/en unknown
- 2019-11-13 CA CA3119239A patent/CA3119239C/en active Active
- 2019-11-13 US US17/293,303 patent/US20220002722A1/en not_active Abandoned
-
2021
- 2021-05-06 SA SA521421963A patent/SA521421963B1/ar unknown
- 2021-05-10 CL CL2021001225A patent/CL2021001225A1/es unknown
- 2021-06-04 CO CONC2021/0007372A patent/CO2021007372A2/es unknown
- 2021-12-22 US US17/559,479 patent/US11499153B2/en active Active
-
2025
- 2025-07-08 US US19/263,110 patent/US20260078372A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3710586T3 (da) | Nukleinsyrer til inhibering af ekspression af LPA i en celle | |
| HUE060703T2 (hu) | Nukleinsavak LPA expressziójának gátlására egy sejtben | |
| IL270990A (en) | Expression of novel cell tags | |
| DK3707723T3 (da) | Teknikker til indeksering af nukleinsyrer | |
| DK3448990T3 (da) | Forbedrede fremgangsmåder til modificering af målnukleinsyrer | |
| EP3780136A4 (en) | CELL | |
| EP4134668C0 (en) | ELECTROPHORETIC CELL | |
| EP3893285A4 (en) | SOLAR CELL | |
| EP3448982A4 (en) | CELL CULTURE MEDIUM | |
| DK3427323T3 (da) | Brændselscelle | |
| DK3775223T3 (da) | Fremgangsmåde til øgning af ekspressionsniveauet for et nukleinsyremolekyle af interesse i en celle | |
| DK3365107T3 (da) | Cellekultur | |
| EP3879591A4 (en) | SOLAR CELL | |
| EP3448986A4 (en) | CELL CULTURE | |
| EP3518302A4 (en) | SOLAR CELL | |
| EP3561042A4 (en) | SCAFFOLDING MATERIAL FOR CELL CULTURE | |
| EP3874059C0 (en) | FULL-LENGTH SINGLE-CELL RNA SEQUENCING | |
| EP3561044A4 (en) | CELL CULTURE SUBSTRATE | |
| PT3710586T (pt) | Ácidos nucleicos para inibir a expressão de lpa numa célula | |
| EP3822336A4 (en) | CELL CULTURE SHEET | |
| EP3413366A4 (en) | SOLAR CELL | |
| EP3699969A4 (en) | SOLAR CELL | |
| EP3829776A4 (en) | FLOTATION CELL | |
| EP3890045A4 (en) | ELECTROCHEMICAL CELL | |
| EP3448816A4 (en) | FLOATING BIOREACTOR |